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Introduction
Vaccinia virus (VACV) belongs to the orthopoxvirus (OPV) genus 
and is closely related to variola virus, the causative agent of smallpox. 
The virions are generally enveloped, contain a double-stranded DNA 
and replicating within the cytoplasm. VACV represents the prototype 
of the OPV genus and had been successfully used as vaccine against 
smallpox which was declared eradicated in 1979 [1]. However, due 
to the severe adverse effects caused in a considerable proportion of 
vaccinees, vaccination was halted soon after eradication. Today, in 
the light of a decreasing immunity in the population, the potential 
abuse of variola virus for bioterrorist purposes is intensively 
discussed [2]. Therefore, and with regard to the increasing number of 
zoonotic infections, the development of strategies to counteract OPV 
infections by introducing new therapeutic and prophylactic measures 
is widely accepted [3].
Sulfated polysaccharides (sPS), in particular dextran sulfate 
(DS) and related polyanionic compounds, have been shown to 
be active against various viruses since the 1960ies [4]. Interest 
in these compounds increased when first studies on anti-human 
immunodeficiency virus (HIV) activities were published [5,6]. Most of 
the studies on the antiviral activity of polyanionic compounds, as well 
as their mode of action, were performed by De Clercq and co-workers 
[7]. Today it is known that the crucial factors for antiviral activity – 
beside the scaffold of a polymer (saccharides, alkyls, aminoacids etc.) 
and the type of anion (sulfate, sulphone, carboxylate, phosphate) 
– are mainly the molecule size, its conformation, charge frequency 
or charge spreading [9]. It is generally assumed that polyanionic 
compounds interact with positively charged viral membrane 
glycoproteins of enveloped viruses and thereby inhibit initial viral 
attachment to negatively charged heparan sulfate proteoglycans 
on the cellular membrane [8]. Referring to VACV, the interaction 
between A27L membrane gene product and heparan sulfate was 
revealed by Chung et al.[10]. Concerning HIV and influenza A virus, 
further specific interactions between sPS and the viral membrane 
have been elucidated in detail (reviewed by Witvrouw et al. [7] and 
Luscher-Mattli [9]. 
Aside from their favored antiviral activities, sPS exhibit 
several undesirable side effects, like anticoagulant activity and 
the induction of severe but reversible thrombocytopenia when 
applied intravenously [11]. Both effects depend on the compound 
structure. To overcome these side effects and isolate improved 
antiviral compounds, we aimed to isolate novel antiviral sPS from 
phototrophic microorganisms.
Phototrophic microorganisms provide a large pool of bioactive 
compounds, and the intensive search for new drugs leads to the 
identification and structure determination of many novel compounds 
from these organisms [12,13,14]. Gustafson and co-workers described 
antiviral activities of sulphoglycolipides isolated from cyanobacteria 
for the first time [14,15]. In addition to sulphoglycolipides 
[14,15,16,17,18], to date lectins [19,20,21,22,23,24] and sPS have 
been discovered to exhibit antiviral activities against HIV-1, HIV-2, 
human cytomegalovirus (HCMV), herpes simplex virus types 1 and 2 
(HSV-1 and HSV-2), denguevirus types 2, 3 and 4 (DENV-2 , DENV-3 
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Abstract
The aim of the present study was to characterise anti-vaccinia virus activities of anionic exopolysaccharides TK V3 
isolated from cyanobacterium Arthrospira platensis and an exopolysaccharide isolated from the rhodophyt Porphyridium 
purpureum, respectively. These substances have previously been shown to be active against other enveloped viruses. 
We determined the in vitro inhibition of GFP-expressing vaccinia virus replication of 50 % at a concentration of 0.65 µg/
ml for EPS and of 0.78 µg/ml for TK V3. Substances also had an antiviral effect against ectromelia virus which is a 
most distinct orthopoxvirus genetically and the causative agent of mousepox. Anti-vaccinia virus and anti-ectromelia 
virus activities were demonstrated to increase with decreasing multiplicity of infection. Furthermore, non-toxic reduction 
of vaccinia virus in ovo replication was shown. Using time-of-addition assays, inhibition of viral entry by polyanionic 
substances was verified. EPS and TK V3 derived from phototrophic microorganisms represent novel anti-orthopoxvirus 
substances.
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and DENV-4), respiratory syncytial virus (RSV), measles virus, mumps 
virus, influenza A virus and other enveloped viruses.
Recently, we have isolated anionic, sulphur-containing 
exopolysaccharides from Porphyridium purpureum (EPS) and 
Arthrospira (formerly Spirulina) platensis (TK V3). TK V3 is different 
from TK V2 which presumably contains the already known sPS 
calcium spirulan (CaSp) that is intracellularly produced [25]. CaSp has 
previously been described to possess antiviral activities against HIV-
1, HCMV, HSV-1, measles virus, mumps virus and influenza A virus 
[26,27,28] TK V3 was shown to inhibit replication of HIV, HCMV, 
HSV-1, human herpesvirus type 6 (HHV-6) and VACV, but not the 
enveloped viruses Epstein-Barr virus and influenza A virus [25] EPS 
isolated from P. purpureum displays antiviral activities against HCMV, 
HHV-6 and VACV [31]. The study presented here was performed to 
investigate in detail anti-VACV activities of EPS and TK V3 in vitro and 
in ovo and to gain insight into the mode of anti-VACV action.
Material and Methods
Antiviral substances
TK V2 (intracellular product from cyanobacterium A. platensis 
NIES 39 and presumably containing the already known CaSp), TK V3 
(extracellular product from A. platensis) and EPS (extracellular 
product from the rhodophyt P. purpureum) were produced and 
structurally described as previously reported [31,32]. Briefly, TK V2 
and TK V3 were isolated from culture supernatant by centrifugation of 
culture broth, lyophilization and dialysis against deionized ultrapure 
water. EPS extraction was performed using chloroform, methyl 
alcohol  and Butanol, followed by cross-flow ultrafiltration with 
deionized ultrapure water, and the extract was finally lyophilised. 
Other extracts isolated according to the same procedure displayed 
no antiviral activity (data not shown). DS (MW 500,000) was used as 
antiviral reference. 
Cells and viruses
HEp-2 cells (ATCC: CCL-23) were cultured in D-MEM (Gibco, 
Paisley, UK) supplemented with 5% foetal bovine serum (PAN Biotech 
GmbH, Aidenbach, Germany) and 1% L-Glutamine (PAA, Pasching, 
Austria). VERO C1008 cells (ATCC: CRL-1586) were cultured in 
D-MEM containing 10% foetal bovine serum and 1% L-Glutamine. 
All cells were maintained in a humidified environment with 5% CO2 
at 37°C, and confluent cells were seeded at the ratio of 1:4 into 
new culture flasks. VACV strain NYCBOH was obtained from ATCC 
(VR-1536). Ectromelia virus (ECTV) strain Nu-1 was obtained from 
Hermann Meyer, Institute of Microbiology, Bundeswehr (Federal 
Armed Forces), Munich, Germany. Recombinant VACV-expressing 
green fluorescent protein (VACV-GFP) was obtained from Rafael 
Blasco, Departamento de Sanidad Animal, Centro de Investigacion en 
Sanidad Animal-INIA, Madrid, Spain. Virus strains were propagated in 
HEp-2 cells at a multiplicity of infection (MOI) of 0.25. Infected cells 
were incubated for 4 days until a distinct cytopathic effect (CPE) was 
observed. Supernatants containing viral particles and infected cells 
were harvested by centrifugation (10 min at 1000 x g) after freeze 
thawing. Supernatants were titrated and stored at -75°C until use.
Cell proliferation tests
5000 HEp-2 cells were seeded as described above in 100µl medium 
per well in a 96-well plate and grown for 24 hours. Subsequently, 
medium was replaced by 100µl of antiviral substance dilution which 
was tested 8-fold in parallel. Substances were incubated at cell growth 
conditions for 48 hours. Following removal of supernatant and cell 
treatment with 10µl of trypsin/EDTA (0.08/0.13%) for 5 min, 100µl 
medium and 10µl WST-1 reagent (Roche, Penzberg, Germany) were 
added. Reaction was incubated for 4 hours and finally dye extinction 
was measured at 450 nm.
Infection in 96-well plates
5 x 103 cells in 100µl medium per well were incubated in a 
humidified environment with 5% CO2 at 37°C. After 24 hours, 
supernatant was removed and cells were infected and treated 
with different concentrations of substances from phototrophic 
microorganisms. A final volume of 100µl per well was adjusted. 
24 hours (VACV), 30 hours (ECTV) and 48 hours (VACV-GFP) p. i., 
respectively, medium was removed and stored at -20°C to perform a 
plaque titration assay later on. The proportion of infected cells was 
calculated after immunofluorescence staining.
Plaque assay
1.2–1.5 x 106 VERO C1008 cells were seeded in 200µl medium 
per well of a 24-well plate. Serial dilutions (10-1–10-6) of 200µl virus-
containing cell culture supernatants were applied in quadruplicate. 
Infection occurred at 37°C for 4–5 hours and was terminated by 
overlaying of 400µl of carboxymethyl cellulose (BDH Ltd., Poole, 
UK). Cells were cultured for 4 further days, subsequently fixed with 
4% formaldehyde for 20 min, stained with 0.1% naphthalene black 
solution (1.7% w/v Naphthol Blue Black [Sigma-Aldrich, Munich, 
Germany] and 22.7% w/v sodium acetate in absolute acetic acid) for 
15 min and finally washed with water. Plaques within the naphthalene 
black cell layer were counted per well.
Immunofluorescence staining
Cells were fixed with 200µl formaldehyde (4%) for 20 min, 
subsequently treated with 70µl Triton X-100 (0.2% in PBS) for 
15 min, afterwards incubated with 50µl human anti-pox antibody 
(Omrigam; Omrix. Biopharmaceutics Ltd, Givat Shmuel, Israel), 1:500 
in diluent buffer [PBS, 2% BSA, 0.2% NaN3] for 1 hour and eventually 
stained with 50µl FITC-conjugated goat anti-human IgG (Caltag 
Laboratories, Burlingame/CA, USA, 1:50 in diluent buffer containing 
200 ng/ml Evan’s Blue) for 1 hour. All incubations were performed 
at room temperature, and between each step cells were thoroughly, 
but carefully, washed with PBS. Volumes of reagents are indicated 
per well. Regarding VACV-GFP-infected cells, only counterstaining 
was performed using 50µl Evan’s Blue (200 ng/ml) for 10 min. To 
determine the ratio of infected cells, representative pictures were 
taken, and infected and non-infected cells were quantified using the 
Wright cell imaging facility ImageJ software (National Institutes of 
Health, Toronto, Canada). The inhibitory substance concentration, 
causing a 50% decrease of viral replication (IC50), was determined 
by plotting the ratio of infected cells per well against the substance 
concentration used and calculated using the equation of a quadratic 
smoothing function.
In ovo tests
Fertile eggs from hens of the breed White Leghorn were 
incubated at 37.7°C and a relative humidity of 50–60% under forced 
air circulation. Before inoculation on day 11, eggs were candled 
to eliminate infertile eggs and dead embryos. Approximately 50µl 
of VACV (100 PFU) and 50µl of antiviral compound (5µg/mL) were 
inoculated simultaneously onto the chorioallantoic membrane (CAM) 
[29,30]. Embryos were incubated at 37°C, examined daily for signs 
of mortality and sampled when the positive control (VACV injection 
only) caused embryos’ death. Four days after infection, chick embryo 
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livers and CAMs were removed and homogenized in 1 mL growth 
medium. Aliquots were processed for standard plaque assay.
Statistics
General calculations were performed with Microsoft Excel. 
Statistical analysis was performed with SPSS.
Results
Substance-induced cytotoxicity
Initially, the in vitro cytotoxicities of TK V3, EPS as well as DS 
were determined. For this purpose, HEp-2 cells were treated with 
each substance for 48 hours and the mitochondrial dehydrogenase 
activity was quantified using WST-1 reagent which directly correlates 
to cellular proliferation. DS as antiviral reference did not exhibit 
any cytotoxic activity at concentrations of up to 50µg/ml. TK V3 
from A. platensis and EPS from P. purpureum were not cytotoxic in 
concentrations of up to 500µg/ml (data not shown).
Antiviral in vitro activity
Antiviral activities of TK V3, TK V2 and EPS against VACV-
GFP were determined by estimating the ratio of infected cells 
48 hours p. i. Figure 1 shows the decrease of the viral load with the 
concentrations of TK V3, EPS and DS, respectively. The IC50 were 
calculated to be 0.78µg/ml for TK V3, 0.65 µg/ml for EPS and 1.24µg/
ml for DS. TK V3 and EPS did not achieve complete viral inhibition 
up to concentrations of 10µg/ml, and DS did not achieve complete 
viral inhibition up to concentrations of 5µg/ml. TK V3 and EPS also 
highly and TK V2 weakly inhibited replication of unlabeled VACV as 
determined by plaque reduction assay 24 hours p. i. (data not shown). 
Table 1 demonstrates that the antiviral activities of the substances 
derived from phototrophic microorganisms are not restricted to the 
HEp-2 host cell type and VACV, but are also detectable in VERO C1008 
host cells infected with a distant relative of VACV, the ectromelia 
virus. TK V3 acts comparably against VACV-GFP and ECTV in HEp-2 
and VERO C1008 cells. Interestingly, EPS activity against VACV-GFP 
in VERO C1008 cells (20% vs. positive control of 68%) is reduced 
compared to HEp-2 cells (54% vs. positive control of 74%). Even if the 
overall infection rates for ectromelia are low, resulting in marginal 
differences for extract-treated cells, the data represent a trend that 
underlines the antiviral effect of the extracts used in VACV infection.
To determine the number of infectious virus particles produced 
by infected cells in the presence and absence of inhibitory substances, 
VERO C1008 cells were infected with VACV and the proportion 
of infected cells analysed 48 hours p.i. In addition, the respective 
supernatants were used for titre determination by plaque test. The 
number of primary infected cells as well as the number of infectious 
virus particles found in the supernatant were decreased by TK V3 and 
EPS, respectively, in a concentration-dependent manner (data not 
shown). 
Furthermore, the antiviral activities of TK V3 and EPS against 
VACV-GFP were analysed in relation to the applied MOI. Figure 2 
illustrates the strong antiviral activities of TK V3 and EPS even for 
high amounts of virus. Even using high MOI = 10, broad antiviral 
activities were observed, with a reduction of about 20% (TK V3) and 
30% (EPS), respectively, at concentrations of 10µg/ml of both antiviral 
substances. Substance activity against ECTV in HEp-2 and VERO 
C1008 cells also correlated with MOI (data not shown).
Antiviral in ovo activity
The CAM of embryonated eggs was treated with EPS and TK V3 
and was simultaneously infected with VACV. Four days p. i. embryo 
vitality (candling) and viral load of CAM and liver extracts (plaque 
assay) were determined, respectively. In contrast to untreated and 
infected embryos, the substance-treated and infected embryos were 
vital even after 4 days p. i. Figure 3 demonstrates the pronounced 
decrease of viral load (> 90%) within the CAM of TK V3- or EPS-treated 
eggs as determined by plaque titration. Viral hepatic replication was 
decreased by 50% and 70%, respectively. Except for non-infected 
controls treated with substance only, all embryos were dead after 
7 days p. i. These data indicate low substance toxicities. 
Of note, in contrast to non-infected and substance-treated 
embryonated eggs, infected and substance-treated deceased 
embryonated eggs smelled of hydrogen sulphide and developed green 
Figure 1:  Antiviral activities of EPS from P. purpureum and TK V3 from A. pla-
tensis against VACV-GFP 48 hours p. i. Viral load is given in percent of the maxi-
mum number of infected cells in the positive control without antiviral substance 
to the number of infected cells in substance-treated cultures; MOI = 0.1  (mean 























HEp-2 68 24 20
VERO C1008 74 27 54
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VERO C1008 9 3 2
Viral load is given in percent of infected cells related to total cell number. Mean 
values of n = 4.

























Figure 2:  Antiviral activities of TK V3 from A. platensis (a) and EPS from P. pur-
pureum (b) against VACV-GFP of varying MOI 48h p. i. Viral load is given in 
percent of infected cells related to total cell number. (Mean values of n = 4.).
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discolorations. It is conceivable that these effects might occur due to 
the high sulphur content of substances derived from phototrophic 
microorganisms which might be reduced to hydrogen sulphide and 
further react to green iron sulphide in non-vital organisms. 
Mode of action
As already mentioned, sPS were shown to act by inhibition of 
the viral entry process by blocking viral membrane glycoproteins. In 
order to reveal the mode of antiviral action of the substances derived 
from phototrophic microorganisms, we performed time-of-addition 
assays. As demonstrated in Figure 4, substances acted best when 
antiviral treatment and infection were performed simultaneously 
(bars B) compared to untreated infections (grey bars, A). Lowest 
antiviral activities were determined when antiviral treatment had 
occurred p. i. (bars C). Good antiviral activities were also detected 
when antiviral treatment was carried out prior to infection (bars D), 
but substances possessed less antiviral activities if they had been 
removed before infection (bars E). These results demonstrate that 
the investigated substances do not interact with cells but with free 
viral particles, which corresponds to the theory about the mode of 
antiviral sPS action. This theory is supported by the observation that 
the virus spread at MOI < 0.1 appeared not to be random via free 
virus in the cell culture supernatant, but occurred mainly from cell 
to cell.
Discussion
Our data indicate that anionic exopolysaccharides (EPS) 
TK V3 from cyanobacterium A. platensis and EPS from rhodophyt 
P. purpureum possess anti-OPV activities. TK V3 had been shown 
to be also active against HCMV, HHV-6, HIV-1 and HSV-1 [31,32] 
and EPS had already been demonstrated to inhibit HCMV and HHV-
6 replication [31]. Using recombinant GFP-expressing VACV, we 
determined IC50 values against VACV of 0.78µg/ml (TK V3) and 0.65µg/
ml (EPS), respectively, compared to 1.24 µg/ml (DS, MW 500.000). 
Hence, compared to DS, the antiviral activity is slightly higher for 
the substances derived from phototrophic microorganisms. The IC50 
determined for DS is significantly lower than that observed by other 
workgroups, e.g. IC50 = 40µg/ml [7], which might be explained by 
differently used virus strains (wild type/GFP-expressing strain) and 
host cell systems (primary rabbit kidney cells/HEp-2 cells). WST-
1 tests did not reveal any inhibition of HEp-2 cell proliferation by 
TK V3 or EPS up to a concentration of 500µg/ml and up to 50µg/ml 
for DS. Thus, the selectivity indices (SI) for VACV in HEp-2 cells can be 
estimated to be SI>640 for TK V3, SI>770 for EPS and SI>40 for DS, 
respectively. Irrespective of the initial MOI, the substances were also 
active against VACV and ECTV in HEp-2 and VERO C1008 cells. Even 
using a high MOI of 10, substances were shown to inhibit the VACV-
GFP replication in a concentration-dependent manner. Furthermore, 
TK V3 and EPS were marginally toxic for embryonated eggs and 
decreased VACV in ovo replication. Thus, the substances are suitable 
for in vivo application in further experiments.
As generally accepted, anionic polysaccharides show antiviral 
activity against enveloped viruses whose initial cellular receptors 
are anionic (sulfated) carbohydrates. They act via inhibition of viral 
membrane glycoproteins [7]. Accordingly, the mechanism of the anti-
VACV action of TK V3 and EPS may be attributed to the inhibition of 
the binding of virus to cells (Figure 4). The results showed that the 
highest antiviral effect can be observed when performing antiviral 
treatment and infection at the same time. The second highest antiviral 
effect was detected by preincubation of virus with the TK V3 and EPS. 
This can be attributed to the concentration changes that occur when 
preincubated antivirals and virus are added to cells. Like all chemical 
processes, this is an equilibrium reaction. The concentration changes 
may lead to a decrease of the anionic polysaccharides on the virus 
membrane for a short time and may allow better virus interaction with 
the cells before the reaction reaches an equilibrium. This antiviral 
mode of action is completely different from that of other known 
anti-VACV drugs, e.g. Cidofovir, Ribavirin, ST-246 or Gleevec, which 
opens the possibility of combinatory therapies and makes further 
investigation into TK V3 and EPS anti-VACV activities advisable.
Intracellular anionic polysaccharide TK V2 from A. platensis 
presumably contains the already known CaSp which was shown to 
be active against various enveloped viruses in vitro, for example 
HSV-1, HIV-1, HCMV, measles virus and influenza A virus [26,33]. 
Surprisingly, TK V2 which is highly active against HIV-1, HSV-1, 
HCMV and HHV-6 in vitro [32], is not active against VACV-GFP up to a 
concentration of 250µg/ml and only weakly inhibitory of VACV strain 
NYCBOH replication. Possibly, disparities in the activities against 
different viruses as well as different VACV strains might be caused by 
single specific variations within viral membrane glycoproteins.
Anionic polysaccharides derived from phototrophic 
microorganisms represent a novel substance group featuring 
various antiviral activities [7,34]. Here we demonstrated the antiviral 
activities of two sulphur-containing anionic exopolysaccharides 
from cyanobacterium A. platensis (TK V3) and from rhodophyt 
P. purpureum (EPS) against the OPV VACV and ECTV.So far, there 
have been few reports of anti-OPV polyanionic activities derived from 
phototrophic microorganisms [8,35]. 
Figure 3:  Antiviral in ovo activities of 0.25 µg TK V3 from A. platensis and 
0.25 µg EPS from P. purpureum against VACV in CAM and liver of chick em-
bryos 4 days p. i. Infection and substance application occurred simultaneously 
on CAM. Viral load was determined by plaque assay and is given in percent of 



































Figure 4:  Variation of the time of addition of 5 µg/µl TK V3 from A. platensis (a) 
or 5 µg/µl EPS from P. purpureum (b) concerning the time point of VACV-GFP 
infection. A: infection without treatment, B: simultaneous infection and antiviral 
treatment, C: antiviral treatment 60 min p. i., D: antiviral treatment 60 min prior 
to infection, E: antiviral treatment for 60 min followed by removal of antiviral 
reagent prior to infection. Viral load is given in percent of infected cells related to 
total cell number. Bars represent mean values of n = 4.
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Production of the compounds in monoseptic cultures of 
microalgae and cyanobacteria occurred in photo-bioreactors and 
can be scaled up successfully [36]. Ionic polysaccharides can easily 
be extracted from culture broth, avoiding extensive separation from 
and elimination of cellular components. From our experience with 
this method, the whole process is highly reproducible. These aspects 
favour further steps towards the development of the compounds as 
potential therapeutic agents.
Conclusion
Our data suggest that anionic polysaccharides TK V3 and EPS 
from phototrophic microorganisms are novel inhibitors of OPV and 
other enveloped viruses. Their in vivo efficacies and bio-availabilities 
as well as their toxicity profile upon systemic and topical application 
have to be studied further. However, anionic polysaccharides may 
be considered for combinatorial treatment with already established 
antiviral substances.
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